Regeneron and Sanofi's COPD Drug Shows Mixed Results in Phase 3 Trials
A key Phase 3 trial of Regeneron and Sanofi's COPD drug, itepekimab, failed to meet its primary endpoint, causing a significant drop in their stock prices, although one of the two trials showed a meaningful benefit. The companies are reviewing the data and consulting with regulators to determine next steps.
